Zhe Ding1, Robert B Raffa. 1. Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA 19140, USA.
Abstract
BACKGROUND AND PURPOSE: Buprenorphine displays attributes of opioids, but also some features distinct from them. We examined spinal and supraspinal signal transduction of buprenorphine-induced anti-nociception in mice compared with morphine and fentanyl. EXPERIMENTAL APPROACH: The opioid receptor antagonist naloxone, Pertussis toxin (PTX), G(z) protein antisense and nociceptin/orphanin-FQ receptor agonist nociceptin, and antagonist, JTC-801, were injected supraspinally (intracerebroventricular) and spinally (intrathecal). Also the cell-permeable Ser/Thr protein phosphatase inhibitor okadaic acid was given supraspinally. KEY RESULTS: Spinal naloxone (20 microg) or PTX (1 microg) attenuated morphine, fentanyl and buprenorphine (s.c.) anti-nociception. Supraspinal naloxone or PTX attenuated morphine and fentanyl, but not buprenorphine anti-nociception. Spinal G(z) protein antisense did not alter buprenorphine, morphine or fentanyl anti-nociception and supraspinal G(z)-antisense did not alter morphine or fentanyl anti-nociception. However, supraspinal G(z)-antisense (not random sense) reduced buprenorphine anti-nociception. Peripheral JTC-801 (1 mgxkg(-1), i.p.) enhanced the ascending (3 mgxkg(-1)) and descending (30 mgxkg(-1)) portions of buprenorphine's dose-response curve, but only spinal, not supraspinal, nociceptin (10 nmolxL(-1)) enhanced buprenorphine anti-nociception. Intracereboventricular okadaic acid (0.001-10 pg) produced a biphasic low-dose attenuation, high-dose enhancement of buprenorphine(3 or 30 mgxkg(-1), s.c.) anti-nociception, but did not affect morphine or fentanyl anti-nociception. CONCLUSIONS AND IMPLICATIONS: Buprenorphine has an opioid component to its supraspinal mechanism of analgesic action. Our present results reveal an additional supraspinal component insensitive to naloxone, PTX and nociceptin/orphanin-FQ, but involving G(z) protein and Ser/Thr protein phosphatase. These data might help explain the unique preclinical and clinical profiles of buprenorphine.
BACKGROUND AND PURPOSE:Buprenorphine displays attributes of opioids, but also some features distinct from them. We examined spinal and supraspinal signal transduction of buprenorphine-induced anti-nociception in mice compared with morphine and fentanyl. EXPERIMENTAL APPROACH: The opioid receptor antagonist naloxone, Pertussis toxin (PTX), G(z) protein antisense and nociceptin/orphanin-FQ receptor agonist nociceptin, and antagonist, JTC-801, were injected supraspinally (intracerebroventricular) and spinally (intrathecal). Also the cell-permeable Ser/Thr protein phosphatase inhibitor okadaic acid was given supraspinally. KEY RESULTS: Spinal naloxone (20 microg) or PTX (1 microg) attenuated morphine, fentanyl and buprenorphine (s.c.) anti-nociception. Supraspinal naloxone or PTX attenuated morphine and fentanyl, but not buprenorphine anti-nociception. Spinal G(z) protein antisense did not alter buprenorphine, morphine or fentanyl anti-nociception and supraspinal G(z)-antisense did not alter morphine or fentanyl anti-nociception. However, supraspinal G(z)-antisense (not random sense) reduced buprenorphine anti-nociception. Peripheral JTC-801 (1 mgxkg(-1), i.p.) enhanced the ascending (3 mgxkg(-1)) and descending (30 mgxkg(-1)) portions of buprenorphine's dose-response curve, but only spinal, not supraspinal, nociceptin (10 nmolxL(-1)) enhanced buprenorphine anti-nociception. Intracereboventricular okadaic acid (0.001-10 pg) produced a biphasic low-dose attenuation, high-dose enhancement of buprenorphine(3 or 30 mgxkg(-1), s.c.) anti-nociception, but did not affect morphine or fentanyl anti-nociception. CONCLUSIONS AND IMPLICATIONS: Buprenorphine has an opioid component to its supraspinal mechanism of analgesic action. Our present results reveal an additional supraspinal component insensitive to naloxone, PTX and nociceptin/orphanin-FQ, but involving G(z) protein and Ser/Thr protein phosphatase. These data might help explain the unique preclinical and clinical profiles of buprenorphine.
Authors: L Toll; I P Berzetei-Gurske; W E Polgar; S R Brandt; I D Adapa; L Rodriguez; R W Schwartz; D Haggart; A O'Brien; A White; J M Kennedy; K Craymer; L Farrington; J S Auh Journal: NIDA Res Monogr Date: 1998-03
Authors: Claire L Neilan; Stephen M Husbands; Simon Breeden; M C Holden Ko; Mario D Aceto; John W Lewis; James H Woods; John R Traynor Journal: Eur J Pharmacol Date: 2004-09-19 Impact factor: 4.432
Authors: Bichoy H Gabra; Chris P Bailey; Eamonn Kelly; Amanda V Sanders; Graeme Henderson; Forrest L Smith; William L Dewey Journal: Brain Res Date: 2007-05-21 Impact factor: 3.252
Authors: Mark K Greenwald; Chris-Ellyn Johanson; David E Moody; James H Woods; Michael R Kilbourn; Robert A Koeppe; Charles R Schuster; Jon-Kar Zubieta Journal: Neuropsychopharmacology Date: 2003-11 Impact factor: 7.853
Authors: G Cristina Brailoiu; Elena Deliu; Robert Hooper; Nae J Dun; Ashiwel S Undieh; Martin W Adler; Khalid Benamar; Eugen Brailoiu Journal: Drug Alcohol Depend Date: 2011-12-21 Impact factor: 4.492
Authors: Steven G Grinnell; Michael Ansonoff; Gina F Marrone; Zhigang Lu; Ankita Narayan; Jin Xu; Grace Rossi; Susruta Majumdar; Ying-Xian Pan; Daniel L Bassoni; John Pintar; Gavril W Pasternak Journal: Synapse Date: 2016-07-12 Impact factor: 2.562